Collegium Pharmaceutical, Inc. (COLL) — Financial statements
Income statement, balance sheet, and cash flow for Collegium Pharmaceutical, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 781↑23.6% | 631↑11.4% | 567↑22.2% | 464↑67.6% | 277 | |
| Cost of Revenue | 317↑24.9% | 254↑5.6% | 241↓5.4% | 254↑101.5% | 126 | |
| Gross Profit | 463↑22.8% | 377↑15.7% | 326↑55.7% | 209↑39.1% | 151 | |
| Operating Expenses | ||||||
| R&D Expenses | 0.00 | 0.00 | 0.00↓100.0% | 4↓57.9% | 9 | |
| General & Administrative Expenses | 0.00↓100.0% | 172 | 0.00 | 0.00 | 0.00 | |
| Selling & Marketing Expenses | 0.00↓100.0% | 11 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 276↑50.9% | 183↑14.9% | 159↓7.5% | 172↑44.7% | 119 | |
| Other Expenses | 0.00↓100.0% | 24 | 0.00 | 0.00↓100.0% | 5 | |
| Operating Expenses | 276↑33.1% | 207↑30.3% | 159↓9.6% | 176↑32.5% | 133 | |
| Total Costs & Expenses | 593↑28.6% | 462↑15.4% | 400↓7.2% | 431↑66.1% | 259 | |
| Operating Results | ||||||
| Operating Income | 187↑10.1% | 170↑1.8% | 167↑401.1% | 33↑89.0% | 18 | |
| Depreciation & Amortization | 226↑33.6% | 169↑13.3% | 149↑7.4% | 139↑101.6% | 69 | |
| EBITDA | 401↑17.4% | 342↑10.8% | 308↑77.9% | 173↑100.2% | 87 | |
| EBIT | 175↑1.4% | 173↑8.5% | 159↑362.9% | 34↑94.8% | 18 | |
| Interest & Other Income | ||||||
| Net Interest Income | -71↓18.4% | -60↑11.4% | -68↓8.9% | -62↓196.0% | -21 | |
| Interest Income | 11↓19.2% | 14↓10.5% | 16↑1391.4% | 1↑8625.0% | 0.01 | |
| Interest Expense | 82↑11.3% | 74↓11.2% | 83↑31.8% | 63↑200.8% | 21 | |
| Non-Operating Income | 12↑559.1% | -3↓133.6% | 8↑853.5% | -1↓8625.0% | -0.01 | |
| Other Income / Expenses | -94↓32.4% | -71↑21.8% | -91↓46.7% | -62↓196.0% | -21 | |
| Income Before Tax | 93↓6.0% | 99↑30.2% | 76↑362.5% | -29↓755.0% | -3 | |
| Income Tax Expense | 30↑1.3% | 29↑6.5% | 28↑817.2% | -4↑94.9% | -75 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | 63↓9.1% | 69↑43.7% | 48↑292.6% | -25↓135.0% | 72 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | 63↓9.1% | 69↑43.7% | 48↑292.6% | -25↓135.0% | 72 | |
| Bottom-Line Net Income | 69↓8.2% | 75↑38.9% | 54↑316.2% | -25↓132.8% | 76 | |
| EPS (Basic) | 1.98↓7.5% | 2.14↑33.8% | 1.60↑316.2% | -0.74↓136.1% | 2.05 | |
| EPS (Diluted) | 1.73↓7.0% | 1.86↑44.2% | 1.29↑274.3% | -0.74↓139.8% | 1.86 | |
| Weighted Average Shares | 32↓1.8% | 32↓4.3% | 34↓0.3% | 34↓3.2% | 35 | |
| Weighted Average Diluted Shares | 40↓1.8% | 40↓3.3% | 42↑23.5% | 34↓17.6% | 41 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.